Basics of Transfusion Medicine

Pediatric Critical Care

Volumn , Issue , 2006, Pages 1185-1198

  Luban, Naomi L C ^a,b  

^a Laboratory Medicine and Pathology   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41149092216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-032301808-1.50078-X     Document Type: Chapter

References (54)

1. Luban NLC Massive transfusion in the neonate. Transfusion Med Rev 1995, 9:200.
2. Luban NLC, Strauss RG, Hume HA Commentary on the safety of red blood cells preserved in extended storage media for neonatal transfusions. Transfusion 1991, 31:229.
3. Strauss RG, Burmeister LF, Johnson K, et al. Feasibility and safety of AS-3 red blood cells for neonatal transfusions. J Pediatr 2000, 136:215-219.
4. Blajchman MA, Dzik S, Vamvakas EC, et al. Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-are conference. Transfus Med Rev 2001, 15:108-135.
5. Mink RB, Pollack MM Effect of blood transfusion on oxygen consumption in pediatric septic shock. Crit Care Med 1990, 18:1087.
6. Simpson MB Platelet transfusion in selected clinical situations. Platelets 1988, American Association of Blood Banks, Arlington, Va,. D.M. Smith, S.H. Summers (Eds.).
7. Gmur J, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991, 338:1223.
8. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002, 42:556-566.
9. Murphy S ABO blood groups and platelet transfusion. Transfusion 1988, 28:401.
10. Skogen B, et al. Minimal expression of blood group A antigen on thrombocytes from A2 individuals. Transfusion 1988, 28:456.
11. Moak JL Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002, 126:1430-1433.
12. Goldsmith JC Plasma component therapy. Pediatric transfusion medicine 1990, Johns Hopkins University Press, Baltimore. N.L.C. Luban (Ed.).
13. Schena FP, Pertosa G Fibronectin and the kidney. Nephron 1988, 48:177.
14. Gerna G, et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis 1992, 166:1236.
15. Minton EJ, et al. Human-cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol 1994, 68:4017.
16. Hillyer CD, et al. The role of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood product. Transfusion 1990, 30:659.
17. Lamberson HV, et al. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening donors for IgM for CMV. J Infect Dis 1988, 157:820.
18. Technical manual of the American Association of Blood Banks 1999, American Association of Blood Banks, Bethesda, Md. ed 13.
19. Wong ECC, Luban NLC Cytomegalovirus and parvovirus transmission by transfusion. Principles of transfusion medicine 2002, Williams & Wilkens, Philadelphia, Lippincott. ed 3. E.C. Rossi (Ed.).
20. Bowden RA, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598.
21. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101:4195-4220.
22. Sloand E, et al. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994, 34:48.
23. Busch MP, Lee TH, Heitman J Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992, 80:2128.
24. Kruskall MS, Lee TH, Assmann SF, et al. Survival of transfused donor white blood cells in HIV-infected recipients. Blood 2001, 98:272-279.
25. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001, 285:1592-1601.
26. Kelsey SM, Newland AC Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 1989, 4:543.
27. Shivdasani RA, et al. Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993, 328:776.
28. Greenbaum BH Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991, 9:1889.
29. McMilin KD, Johnson RL HLA homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease. Transfusion Med Rev 1993, 7:37.
30. Ohto H, Anderson KC Post-transfusion graft-versus-host disease in Japanese newborns. Transfusion 1996, 36:117.
31. Strauss RG Data-driven blood banking practices for neonatal RBC transfusions. Transfusion 2000, 40:1528-1540.
32. Roberts GT, Sacher RA Transfusion-associated graft versus host disease. Principles of transfusion medicine 1996, Williams & Wilkins, Baltimore. ed 2. E.C. Rossi (Ed.).
33. Akahoshi M, et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992, 32:169.
34. Pelszynski MM, et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994, 83:1683.
35. Davey RJ, et al. The effect of pre-storage irradiation on post-transfusion red cell survival. Transfusion 1992, 32:525.
36. Eastlund DT, Charbonneau TT Superoxide generation and cytotoxic response of irradiated neutrophils. Transfusion 1988, 28:368.
37. Heuft HG, Goudeva L, Sel S, et al. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 microg/kg) plus dexamethasone versus glycosylated G-CSF (12 microg/kg) alone. Transfusion 2002, 42:928-934.
38. Price TH Granulocyte transfusion in the G-CSF era. Int J Hematol 2002, 76(Suppl 2):77-80.
39. Dodd RY, Notari EP, Stramer SL Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42:975-979.
40. Busch MP, Klineman SH, Nemo GJ Current and emerging infectious risks of blood transfusions. JAMA 2003, 289:926-959.
41. Krafte-Jacobs B, et al. Erythropoietin response to critical illness. Crit Care Med 1994, 22:821.
42. Hawkins ML, Cue JI, DiPiro JT Erythropoietin response to anemia of severe injury. Crit Care Med 1994, 22:A63. abstract.
43. Krafte-Jacobs B, Bock GH The relationship of erythropoietin and interleukin-6 in children with sepsis. Crit Care Med 1996, 24:1455-1459.
44. Vasko SD, et al. Evaluation of erythropoietin levels in the anemia of thermal injury. J Burn Care Rehabil 1991, 12:437.
45. Deitch EA, Sittig KM A serial study of the erythropoietic response to thermal injury. Ann Surg 1993, 217:293.
46. Poletes GP, et al. Blood use in the burn unit: a possible role for erythropoietin. J Burn Care Rehabil 1994, 15:37.
47. Fleming RYD, et al. The effect of erythropoietin in normal healthy volunteers and pediatric patients with burn injuries. Surgery 1992, 112:424.
48. Still JM, et al. A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995, 38:233.
49. Vamvakas EC, Strauss RG Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion 2001, 41:406-415.
50. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001, 108:934-942.
51. Hebert PC, et al. Transfusion requirements in critical care. JAMA 1995, 273:1439.
52. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409-417.
53. Goodman AM, Pollack MM, Patel KM, et al. Pediatric red blood cell transfusions increase resource use. J Pediatr 2003, 142:123-127.
54. Gould SA, Moore EE, Hoyt DB, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002, 195:445-452.